Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Protez Pharmaceuticals

Drug Profile

Research programme: antibacterials - Protez Pharmaceuticals

Alternative Names: Antibacterials for slow-growing and biofilm bacteria - Protez Pharmaceuticals; Bacteriocidal potentiators research programme - Protez Pharmaceuticals; Efflux pump inhibitors research programme - Protez Pharmaceuticals; INF 401; INF-271,468; Research programme: bacteriocidal potentiators - Protez Pharmaceuticals; Research programme: efflux pump inhibitors - Protez Pharmaceuticals

Latest Information Update: 06 Jun 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protez Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 06 Jun 2008 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
  • 23 Sep 2005 This programme is still in active development - BIO-2005 Annual International Convention (BIO-2005)
  • 02 Mar 2004 Influx has been acquired by, and merged into, Protez Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top